BRYAN BURT to Tumor Microenvironment
This is a "connection" page, showing publications BRYAN BURT has written about Tumor Microenvironment.
Connection Strength
0.791
-
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res. 2025 Jul 01; 31(13):2639-2654.
Score: 0.160
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
Score: 0.135
-
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Res. 2022 07 18; 82(14):2593-2609.
Score: 0.130
-
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
Score: 0.097
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.
Score: 0.043
-
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026 08; 172(2):433-449.e10.
Score: 0.042
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024 07 08; 42(7):1202-1216.e8.
Score: 0.037
-
Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer. Sci Adv. 2022 11 18; 8(46):eabq0615.
Score: 0.033
-
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Br J Cancer. 2022 11; 127(9):1691-1700.
Score: 0.033
-
A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Med. 2022 01 12; 14(1):5.
Score: 0.031
-
Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2020 04; 159(4):1598-1610.e3.
Score: 0.027
-
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight. 2016 11 03; 1(18):e89020.
Score: 0.022